NCT03101514View on ClinicalTrials.gov

Kanglaite Reduce the Toxicity of Radiotherapy of Head and Neck Cancer Phase II Study

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

February 1, 2021

Study Completion Date

February 1, 2021

Conditions
Head and Neck CancerRadiotherapy
Interventions
DRUG

Kanglaite

Kanglaite injection 200ml is injected intravenous from the first day to the last day of radiotherapy.

DRUG

chemotherapy

Cisplatin 80-100mg/m2 was used every 3 weeks during radiotherapy.

Trial Locations (1)

150001

First Affiliated Hospital of Harbin Medical University, Harbin

All Listed Sponsors
lead

First Affiliated Hospital of Harbin Medical University

OTHER

NCT03101514 - Kanglaite Reduce the Toxicity of Radiotherapy of Head and Neck Cancer Phase II Study | Biotech Hunter | Biotech Hunter